Focused On-demand Library for Bone morphogenetic protein 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Bone morphogenetic protein 2B

Alternative UPACC:

P12644; Q9UM80


Bone morphogenetic protein 4 (BMP4), also known as Bone morphogenetic protein 2B, is a pivotal growth factor belonging to the TGF-beta superfamily. It orchestrates numerous developmental processes, including neurogenesis, vascular development, angiogenesis, and osteogenesis. BMP4 triggers the canonical BMP signaling cascade by interacting with BMPR1A and BMPR2 receptors, leading to the phosphorylation of SMAD1/5/8, which modulate gene transcription in the nucleus. Additionally, BMP4 can activate non-canonical pathways such as ERK/MAP kinase, PI3K/Akt, or SRC cascades.

Therapeutic significance:

BMP4's involvement in diseases like Microphthalmia, syndromic 6, and Non-syndromic orofacial cleft 11 underscores its potential as a target for therapeutic intervention. Understanding the role of Bone morphogenetic protein 4 could open doors to potential therapeutic strategies, particularly in addressing congenital anomalies and promoting tissue regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.